Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer

BACKGROUND: Circulating tumor DNA (ctDNA) has been proven as a marker for detecting minimal residual diseases following systemic therapies in mid-to-late-stage non-small-cell lung cancers (NSCLCs) by multiple studies. However, fewer studies cast light on ctDNA-based MRD monitoring in early-to-mid-st...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Siwei, Li, Ming, Zhang, Jingyuan, Xing, Peng, Wu, Min, Meng, Fancheng, Jiang, Feng, Wang, Jie, Bao, Hua, Huang, Jianfeng, Ren, Binhui, Yu, Mingfeng, Qiu, Ninglei, Li, Houhuai, Yuan, Fangliang, Zhang, Zhi, Jia, Hui, Lu, Xinxin, Zhang, Shuai, Wang, Xiaojun, Xu, Youtao, Xia, Wenjia, Liu, Tongyan, Xu, Weizhang, Xu, Xinyu, Sun, Mengting, Wu, Xue, Shao, Yang, Wang, Qianghu, Dai, Juncheng, Qiu, Mantang, Wang, Jinke, Zhang, Qin, Xu, Lin, Shen, Hongbing, Yin, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526343/
https://www.ncbi.nlm.nih.gov/pubmed/36183093
http://dx.doi.org/10.1186/s13045-022-01355-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526343/
https://www.ncbi.nlm.nih.gov/pubmed/36183093
http://dx.doi.org/10.1186/s13045-022-01355-8

Ejemplares similares